Following this puts new work involving it at the top of your briefing, with a note saying why it is there. Links are taken from the source record, never inferred.
Cross-sectional study in a single-sex, geographically limited cohort using surrogate measures (visceral fat, liver stiffness, lipid indices) without hard clinical outcomes; findings are descriptive and hypothesis-generating rather than definitive.
Prospective cohort study with 19.6-year median follow-up, hard clinical endpoint (incident ASCVD), and consistent dose–response relationships across multiple abdominal obesity measures with statistical significance and robust sensitivity analyses.
This is a narrative review synthesizing current understanding of cardiovascular-kidney-metabolic syndrome and hepatic involvement, offering diagnostic and therapeutic recommendations rather than reporting original research evidence.
A prospective cohort study with adequate sample size and multivariate adjustment showing a graded dose-response association between modified cardiometabolic index and stroke risk in a high-risk population, but limited by observational design, moderate effect sizes, and lack of established clinical utility.
A single-centre retrospective cohort study identifying clinically plausible risk stratification patterns using routine OGTT and BMI, but explicitly not yet validated for individual prediction or clinical management.
A cross-sectional cluster analysis of registry data identifying five obesity phenotypes; descriptive and hypothesis-generating rather than testing a causal relationship or clinical outcome, and without a comparator or intervention effect.
Cross-sectional analysis of a large occupational cohort confirming that BMI-normal adults exhibit metabolic heterogeneity and hidden cardiometabolic risk not detected by weight-based screening alone, replicating established knowledge that adiposity and metabolic dysfunction may diverge.
A well-designed multivariate genome-wide association study with discovery and validation cohorts identifying 79 susceptibility loci for metabolic syndrome; findings are replicable but represent discovery in a specific population without functional or clinical validation.